Animal Models of Pulmonary Vascular Disease and Therapy Archives - Page 3 of 19

GCN2 kinase activation mediates pulmonary vascular remodeling and pulmonary arterial hypertension

Maggie M. Zhu, Jingbo Dai, Zhiyu Dai, Yi Peng, You-Yang ZhaoNorthwestern University Feinberg School of Medicine.United States Journal of Clinical Investigation InsightJCI Insight 2024; DOI: 10.1172/jci.insight.177926 AbstractPulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary vascular resistance and remodeling that result in right heart failure. Recessive mutations of EIF2AK4 gene (encoding GCN2, General control […]

GCN2 kinase activation mediates pulmonary vascular remodeling and pulmonary arterial hypertension Read More »

G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease

Christina Signoretti, Shun Matsumura, Samuel Fatehi, Melinee D’Silva, Rajamma Mathew, Francesca Cendali, Angelo D’Alessandro, S. M. Shafiqul Alam, Victor Garcia, Joseph M. Miano, Sachin A. GupteNew York Medical College. University of Colorado Anschutz Medical Campus. Medical College of Georgia at Augusta University. United States Journal of the American Medical AssociationJ Am Heart Assoc 2024; DOI: 10.1161/JAHA.123.035174 AbstractBackground: G6PD (glucose-6-phosphate-dehydrogenase) is a key enzyme in the glycolytic pathway and has been implicated in the pathogenesis of cancer

G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease Read More »

Unraveling the Mfn2-Warburg effect nexus: a therapeutic strategy to combat pulmonary arterial hypertension arising from catch-up growth after IUGR

Lingling Yan, Xiaofei Luo, Chengcheng Hang, YuWang, Ziming Zhang, Shanshan Xu, Lizhong DuChildren’s Hospital and First Affiliated Hospital of Zhejiang University School of Medicine. China Respiratory ResearchRespir Res 2024; 25: DOI: 10.1186/s12931-024-02957-1 AbstractBackground: The interplay between intrauterine and early postnatal environments has been associated with an increased risk of cardiovascular diseases in adulthood, including pulmonary arterial hypertension

Unraveling the Mfn2-Warburg effect nexus: a therapeutic strategy to combat pulmonary arterial hypertension arising from catch-up growth after IUGR Read More »

Classical dendritic cells contribute to hypoxia-induced pulmonary hypertension

Claudia Mickael, Linda A. Sanders, Michael H. Lee, Rahul Kumar, Dara Fonseca- Balladares, Aneta Gandjeva, Kelly Cautivo-Reyes, Biruk Kassa, Sushil Kumar, David Irwin, Delaney Swindle, Tzu Phang, Robert S. Stearman, Ari B. Molofsky, Amy S. MxKee, Kurt R. Stenmark, Brian B. Graham, Rubin M. TuderUniversity of Colorado. University of California San Francisco. Zuckerberg San Francisco

Classical dendritic cells contribute to hypoxia-induced pulmonary hypertension Read More »

Lung EC-SOD Overexpression Prevents Hypoxia-Induced Platelet Activation and Lung Platelet Accumulation

Daniel Colon Hidalgo, Mariah Jordan, Janelle N. Posey, Samuel D. Burciaga, Thi-Tina N. Nguyen, Christina Sul, Caitlin V. Lewis 2, Cassidy Delaney, Eva S. NozikUniversity of Colorado Anschutz Medical Campus. United States AntioxidantsAntioxidants 2024; 13: DOI: 10.3390/antiox13080975 AbstractPulmonary hypertension (PH) is a progressive disease marked by pulmonary vascular remodeling and right ventricular failure. Inflammation and oxidative

Lung EC-SOD Overexpression Prevents Hypoxia-Induced Platelet Activation and Lung Platelet Accumulation Read More »

Impact of Right Ventricular Pressure Overload on Myocardial Stiffness Assessed by Natural Wave Imaging

Maelys Venet, Aimen Malik, Samantha Gold, Naiyuan Zhang, Josh Gopaul, John Dauz, Kana Yazaki, Matteo Ponzoni, John C. Coles, Jason T. Maynes, Mai Sun, Alison Howell, Rajiv Chaturvedi, Luc Mertens, Dariusz, Mroczek, Kiyoshi Uike, Jerome Baranger, Mark K. Friedberg, Olivier VillemainHospital for Sick Children. Bordeaux University Hospital.Canada and France Journal of the American College of

Impact of Right Ventricular Pressure Overload on Myocardial Stiffness Assessed by Natural Wave Imaging Read More »

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression

Ekaterina Legchenko, Philippe Chouvarine, Fatimunnisa Qadri, Edgar Specker, Marc Nazaré, Radoslaw Wesolowski, Susann Matthes, Michael Bader, Georg HansmannHannover Medical School. Max-Delbrück-Center for Molecular Medicine. Trypto Therapeutics GmbH. German Center for Cardiovascular Research. Charité Universitätsmedizin Berlin. University of Lübeck. Friedrich-Alexander-University Erlangen-Nürnberg. Germany Journal of the Amerian College of Cardiology Basic to Translational ScienceJACC Basi Transl Sci

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression Read More »

Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension

Jason Hong, Lejla Medzikovic, Wasila Sun, Brenda Wong, Grégoire Ruffenach, Christopher J. Rhodes, Adam Brownstein, Lloyd L. Liang, Laila Aryan, Min Li, Arjun Vadgama, Zeyneb Kurt, Tae-Hwi Schwantes-An, Elizabeth A. Mickler, Stefan Gräf, Mélanie Eyries, Katie A. Lutz, Michael W. Pauciulo, Richard C. Trembath, Frédéric Perros, David Montani, Nicholas W. Morrell, Florent Soubrier, Martin R.

Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension Read More »

Levosimendan mediates the BMP/Smad axis through upregulation of circUSP34-targeted miR-1298 to alleviate pulmonary hypertension

Qiang Meng, Linhong Song, Hui Wang, Gang Wang, Gengxu ZhouSeventh Medical Center of the PLA General Hospital. Southern Medical University. China Respiratory ResearchRespir Res 2024; 25: DOI: 10.1186/s12931-024-02945-5 AbstractBackground: Pulmonary hypertension (PH) is a long-term disease that impacts approximately 1% of the world’s population. Currently, levosimendan (Lev) is proposed for PH treatment. However, the mechanism of Lev

Levosimendan mediates the BMP/Smad axis through upregulation of circUSP34-targeted miR-1298 to alleviate pulmonary hypertension Read More »